PHO On Other Exchanges

photocure asa (PHO) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for PHOTOCURE ASA (PHO)

Related News

No related news articles were found.

photocure asa (PHO) Related Businessweek News

No Related Businessweek News Found

photocure asa (PHO) Details

Photocure ASA, a specialty pharmaceutical company, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products and related technical medical equipment in Nordic countries and the United States. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It is also developing Visonac that has completed Phase IIb study for the treatment of moderate to severe acne; and Cevira, which has completed Phase IIb study for the treatment of human papilloma virus infection and precancerous lesions of the cervix. The company sells its products to license partners, pharmaceutical wholesalers, and hospitals. Photocure ASA was founded in 1997 and is headquartered in Oslo, Norway.

71 Employees
Last Reported Date: 04/17/19
Founded in 1997

photocure asa (PHO) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

photocure asa
PhotoCure ASA, Q1 2019 Earnings Call, May 14, 2019

PhotoCure ASA, Q1 2019 Earnings Call, May 14, 2019

Photocure Group Reports Earnings Results for the First Quarter of 2019

Photocure Group reported earnings results for the first quarter of 2019. For the quarter, the company reported total revenues of NOK 52,198,000 against NOK 41,557,000 a year ago. LBIT including restructuring was NOK 5,764,000 against NOK 7,262,000 a year ago. Net loss was NOK 4,911,000 against NOK 3,002,000 a year ago. Net loss per share, diluted was NOK 0.23 against NOK 0.14 a year ago.

PhotoCure ASA Announces Study of Patients Who Undergo Bladder Tumor Resection with Blue Light Cystoscopy with Hexvix®

PhotoCure ASA announced that a study published in World Journal of Urology, shows that patients who undergo bladder tumor resection with Blue Light Cystoscopy with Hexvix exhibit improved outcomes even if they progress to disease stages which require radical cystectomy. Beneficial long-term impact of BLC with Hexvix was published in an article by Renninger et al. in World Journal of Urology: The prognostic impact of hexaminolevulinate-based bladder tumor resection in patients with primary non-muscle invasive bladder cancer treated with radical cystectomy. A retrospective study on 131 patients demonstrated improved cancer -specific (CSS) and overall (OS) 5-year survival for patients undergoing at least one TURBT (transurethral resection of bladder tumor) guided by BLC with Hexvix compared to white light cystoscopy (WLC) alone for non -muscle invasive cancer (NMIBC) prior to radical cystectomy (RC). The 5-year CSS was 90.9% for the BLC group and 73.8% for the WLC group, and 5-year OS was 74.5% and 55.8% for BLC and WLC groups, respectively (p= 0.042, 0.038). Median follow-up was 38 months (IQR 1356). The BLC -group was associated with a higher number of TURBTs prior to RC (p = 0.002) and administration of intravesical chemotherapy (p = 0.043). In conclusion, the data suggest that the resection of NMIBC under BLC exerts a beneficial impact on outcomes of patients who will need to undergo RC during their course of disease. This finding may be due to improved risk stratification as the resection under BLC may allow more patients to be treated timely and adequately.


The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

PHO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PHO.
View Industry Companies

Industry Analysis


Industry Average

Valuation PHO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.1x
Price/Book 5.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.6x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact PHOTOCURE ASA, please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at